Its either now or never as it reaches previous high testBreak the candle and move on to the 52-week test. This has been turbulent up and down, and there is no escaping the current path to its momentum unless we see a break in structure.
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.00 EUR
−517.38 M EUR
10.61 B EUR
256.31 M
About Vertex Pharmaceuticals Incorporated
Sector
Industry
CEO
Reshma Kewalramani
Website
Headquarters
Boston
Founded
1989
FIGI
BBG00KGFV1H9
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
another flush from a promising start 450 not farThe stock swings have been trying to position themselves into an upswing trending faction. However, they have failed to materialize and have LS from making new highs, an early indication that things may need re-evaluation.
VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH
(1/9)
Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀
(2/9) – REVENUE RUSH
• Q4 Haul: $ 2.91B—16% jump from l
$VRTX with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for NASDAQ:VRTX after a negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 85.71%.
Vertex Pharmaceuticals Pulls Back After RallyVertex Pharmaceuticals ended January with a big rally. Now, after a pullback, some traders may see an opportunity.
The first pattern on today’s chart is the price gap on January 31 after the FDA approved its Journavx painkiller. (It’s the first of its kind to treat pain in a unique way without addi
Can Pain Be Managed Without Addiction?Vertex Pharmaceuticals has achieved a monumental breakthrough in pain management, securing FDA approval for Journavx, the first new class of painkiller in over 20 years. This non-opioid drug introduces a paradigm shift, targeting pain signals directly at the source without the addictive risks associ
Reversal on Vertex Pharmaceuticals. VRTXMean reversion strategy in a fade for the most recent rally. Here, we are betting that the rally, now in OBOS, will not cross the most recent high of highs. More specifically, that the price action will not exceed one std deviation of the vWAP value. There are divergences on the indicators below to
$VRTX, Long, TP>25% NASDAQ:VRTX , Long, TP>25%
Fundamentally the stock is good.
Choose an entry point and do not forget about a protective order if you are trading with leverage.
Don't risk it if you're not sure.
Good luck to everyone.
VRTX"A quick trade for traders based on a classic, well-known pattern: Symmetrical Triangle. Entry at $500, stop loss at $460. First target between $527.5 _ $535. Second target between $544 _ $549."
VRTXThe VRTX stock has broken the ascending channel and successfully retested it. It is now ready to be sold with a first target between $404.60 and $403, and a second target of $375.50. The stop loss is at $500.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where 4VRTX is featured.
Related stocks
Frequently Asked Questions
The current price of 4VRTX is 440.40 EUR — it has increased by 3.04% in the past 24 hours. Watch VERTEX PHARMACEUTICALS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EUROTLX exchange VERTEX PHARMACEUTICALS stocks are traded under the ticker 4VRTX.
4VRTX stock has risen by 2.44% compared to the previous week, the month change is a −7.06% fall, over the last year VERTEX PHARMACEUTICALS has showed a 16.93% increase.
We've gathered analysts' opinions on VERTEX PHARMACEUTICALS future price: according to them, 4VRTX price has a max estimate of 543.51 EUR and a min estimate of 290.69 EUR. Watch 4VRTX chart and read a more detailed VERTEX PHARMACEUTICALS stock forecast: see what analysts think of VERTEX PHARMACEUTICALS and suggest that you do with its stocks.
4VRTX reached its all-time high on Nov 5, 2024 with the price of 487.60 EUR, and its all-time low was 117.05 EUR and was reached on Dec 6, 2017. View more price dynamics on 4VRTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
4VRTX stock is 1.84% volatile and has beta coefficient of 0.72. Track VERTEX PHARMACEUTICALS stock price on the chart and check out the list of the most volatile stocks — is VERTEX PHARMACEUTICALS there?
Today VERTEX PHARMACEUTICALS has the market capitalization of 112.29 B, it has decreased by −3.16% over the last week.
Yes, you can track VERTEX PHARMACEUTICALS financials in yearly and quarterly reports right on TradingView.
VERTEX PHARMACEUTICALS is going to release the next earnings report on May 5, 2025. Keep track of upcoming events with our Earnings Calendar.
4VRTX earnings for the last quarter are 3.84 EUR per share, whereas the estimation was 3.88 EUR resulting in a −0.90% surprise. The estimated earnings for the next quarter are 3.93 EUR per share. See more details about VERTEX PHARMACEUTICALS earnings.
VERTEX PHARMACEUTICALS revenue for the last quarter amounts to 2.81 B EUR, despite the estimated figure of 2.69 B EUR. In the next quarter, revenue is expected to reach 2.65 B EUR.
4VRTX net income for the last quarter is 881.94 M EUR, while the quarter before that showed 938.92 M EUR of net income which accounts for −6.07% change. Track more VERTEX PHARMACEUTICALS financial stats to get the full picture.
No, 4VRTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 6.1 K employees. See our rating of the largest employees — is VERTEX PHARMACEUTICALS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VERTEX PHARMACEUTICALS EBITDA is 23.38 M EUR, and current EBITDA margin is 41.56%. See more stats in VERTEX PHARMACEUTICALS financial statements.
Like other stocks, 4VRTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMACEUTICALS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VERTEX PHARMACEUTICALS technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VERTEX PHARMACEUTICALS stock shows the buy signal. See more of VERTEX PHARMACEUTICALS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.